



**National Collaborative for Innovation in Quality Measurement**  
***Metabolic Monitoring for Children and Adolescents on Antipsychotics***

**Administrative Specification for State Reporting.....Page 2**

**Administrative Specification for Health Plan Reporting.....Page 3**

## Administrative Specification – State Level

### Measure Description

The percentage of children and adolescents 1 to 20 years of age who had two or more antipsychotic prescriptions and had metabolic monitoring during the measurement year.

**Note:** A higher rate indicates better performance.

### Eligible Population

**Ages** 1 to 20 years by December 31 of the measurement year. Report four age stratifications and a total rate.

- 1-5 years
- 6-11 years
- 12-17 years
- 18-20 years
- Total.

The total is the sum of the age stratifications.

**Continuous Enrollment** At least 12 months.

**Allowable Gap** No more than one gap in enrollment of up to 45 days during the measurement year.

**Benefits** Medical and Pharmacy.

**Event/diagnosis** At least two antipsychotic medication dispensing events (Table 1), regardless if they are the same or different medications, on different dates of service during the measurement year.

### Numerator

Both of the following during the measurement year.

- At least one test for blood glucose (Glucose Tests Value Set) or HbA1c (HbA1c Tests Value Set)
- At least one tests for LDL-C (LDL-C Tests Value Set) or cholesterol (Cholesterol Tests Other than LDL Value Set).

### Exclusions

None

**Table 1. Antipsychotic Medications**

| Description                                 | Prescription  |
|---|---|
| First Generation Antipsychotic Medications  | <ul style="list-style-type: none"> <li>• Chlorpromazine hcl</li> <li>• Fluphenazine hcl</li> <li>• Fluphenazine decanoate</li> <li>• Fluphenazine enanthate</li> <li>• Haloperidol</li> <li>• Haloperidol decanoate</li> <li>• Haloperidol lactate</li> <li>• Loxapine hcl</li> <li>• Loxapine succinate</li> <li>• Molindone hcl</li> <li>• Perphenazine</li> <li>• Pimozide</li> <li>• Promazine hcl</li> <li>• Thioridazine hcl</li> <li>• Thiothixene</li> <li>• Thiothixene hcl</li> <li>• Trifluoperazine hcl</li> <li>• Triflupromazine hcl</li> </ul> |
| Second Generation Antipsychotic Medications | <ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Clozapine</li> <li>• Iloperidone</li> <li>• Olanzapine</li> <li>• Olanzapine pamoate</li> <li>• Paliperidone</li> <li>• Paliperidone palmitate</li> <li>• Quetiapine fumarate</li> <li>• Risperidone</li> <li>• Risperidone microspheres</li> <li>• Ziprasidone hcl</li> <li>• Ziprasidone mesylate</li> </ul>   |
| Combinations                                | <ul style="list-style-type: none"> <li>• Olanzapine-fluoxetine hcl (Symbyax)</li> <li>• Perphenazine-amitriptyline hcl (Etrafon, Triavil [various])</li> </ul>  |

## Administrative Specification – Health Plan Level

### Description

The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

### Eligible Population

|                              |   |
|------------------------------|---|
| <b>Product lines</b>         | Commercial, Medicaid (report each product line separately).   |
| <b>Ages</b>                  | 1 year of age to 17 years as of December 31 of the measurement year. Report three age stratifications and a total rate: <ul style="list-style-type: none"><li>• 1–5 years.</li><li>• 6–11 years.</li><li>• 12–17 years.</li><li>• Total.</li></ul> The total is the sum of the age stratifications. |
| <b>Continuous enrollment</b> | The measurement year.   |
| <b>Allowable gap</b>         | No more than one gap in enrollment of up to 45 days during the measurement year.  |
| <b>Anchor date</b>           | December 31 of the measurement year.  |
| <b>Benefit</b>               | Medical and pharmacy.   |
| <b>Event/diagnosis</b>       | At least two antipsychotic medication dispensing events (Table XXX-A), regardless if they are the same or different medications, on different dates of service during the measurement year.   |

### Administrative Specification

|                    |   |
|--------------------|---|
| <b>Denominator</b> | The eligible population.  |
| <b>Numerator</b>   | Both of the following during the measurement year. <ul style="list-style-type: none"><li>• At least one test for blood glucose (<u>Glucose Tests Value Set</u>) or HbA1c (<u>HbA1c Tests Value Set</u>).</li><li>• At least one test for LDL-C (<u>LDL-C Tests Value Set</u>) or cholesterol (<u>Cholesterol Tests Other Than LDL Value Set</u>).</li></ul> |

**Table XXX-A. Antipsychotic Medications**

| Description                                 | Prescription  |  |
|---|---|--|
| First Generation Antipsychotic Medications  | <ul style="list-style-type: none"> <li>• Chlorpromazine hcl</li> <li>• Fluphenazine hcl</li> <li>• Fluphenazine decanoate</li> <li>• Fluphenazine enanthate</li> <li>• Haloperidol</li> <li>• Haloperidol decanoate</li> <li>• Haloperidol lactate</li> <li>• Loxapine hcl</li> <li>• Loxapine succinate</li> </ul> | <ul style="list-style-type: none"> <li>• Molindone hcl</li> <li>• Perphenazine</li> <li>• Pimozide</li> <li>• Promazine hcl</li> <li>• Thioridazine hcl</li> <li>• Thiothixene</li> <li>• Thiothixene hcl</li> <li>• Trifluoperazine hcl</li> <li>• Triflupromazine hcl</li> </ul> |
| Second Generation Antipsychotic Medications | <ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Clozapine</li> <li>• Iloperidone</li> <li>• Olanzapine</li> <li>• Olanzapine pamoate</li> <li>• Paliperidone</li> </ul>  | <ul style="list-style-type: none"> <li>• Paliperidone palmitate</li> <li>• Quetiapine fumarate</li> <li>• Risperidone</li> <li>• Risperidone microspheres</li> <li>• Ziprasidone hcl</li> <li>• Ziprasidone mesylate</li> </ul>  |
| Combinations                                | <ul style="list-style-type: none"> <li>• Olanzapine-fluoxetine hcl (Symbyax)</li> </ul>   | <ul style="list-style-type: none"> <li>• Perphenazine-amitriptyline hcl (Etrafon, Triavil [various])</li> </ul>  |

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 1, 2014.

### Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table XXX-1/2: Data Elements for Metabolic Monitoring for Children and Adolescents on Antipsychotics**

|  | Administrative                        |
|--|---------------------------------------|
| Measurement year                             | ✓                                     |
| Data collection methodology (Administrative) | ✓                                     |
| Eligible population                          | For each age stratification and total |
| Numerator events by administrative data      | For each age stratification and total |
| Reported rate                                | For each age stratification and total |
| Lower 95% confidence interval                | For each age stratification and total |
| Upper 95% confidence interval                | For each age stratification and total |